Thermo Fisher’s Patheon division has signed an exclusive agreement with AustinPx to install the Texas CDMO’s KinetiSol technology at Patheon’s Bend, Oregon, and Cincinnati sites. AustinPx specializes in bioavailability enhancement for orally delivered small molecules, and the placement plugs into Patheon’s Quadrant 2 platform, which applies AI/ML to formulation prediction. It expands access to KinetiSol-enabled…
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
Technology transfer enables the movement of documented processes and knowledge from one unit, such as R&D, a pilot plant or an existing manufacturing site, to another, such as an internal site, CMO or CDMO. However, tacit knowledge, expertise that can’t be written down, is often lost in the process. As of 2022, over 86% of…

